Two monoclonal immunoglobulin Gl antibodies reacting with Cryptococcus neoformans capsular polysaccharide (CNPS) were produced in mice by using a carefully defined procedure for immunization with unmodified CNPS purified from C. neoformans serotype A. Since the antibodies were found to have the same pattern of specificity, only one of them (El) is described. This anti-CNPS monoclonal antibody reacted with the glucuronoxylomannan component of CNPS but not with the constituent monosaccharides or with the mannose ot(1-*3)-linked oligosaccharide structures present on CNPS. E1 appeared to be specific for C. neoformans serotype A by agglutination of whole cells; it was specific for soluble CNPS A by gel immunoprecipitation. However, indirect immunofluorescence and competitive-binding enzyme-linked immunosorbent assay experiments showed low levels of cross-reactivity with serotypes B and D but not with serotype C. Concentrations 10,000 times higher for serotypes B and D cells than for serotype A cells were required for a 50% inhibition of El anti-CNPS A activity as measured by enzyme-linked immunosorbent assay. Among the other yeasts tested, a cross-reaction was only detected with Trichosporon beigelii. The four serotypes of C. neoformans could be distinguished based on intensities and patterns of fluorescence in an indirect immunofluorescence assay using the monoclonal anti-CNPS A antibody. Monoclonal anti-CNPS A antibodies could be useful for fundamental studies on the glucuronoxylomannan structure, as well as for clinical applications such as serotyping and possibly the serological diagnosis of cryptococcosis.
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Cryptococcus neoformans is a yeastlike encapsulated fungus responsible for life-threatening infections in immunocompromised hosts (16, 21) . Anti-C. neoformans antibodies, raised in rabbits after active immunization and then properly absorbed, are used for the serotyping of C. neoformans clinical isolates by agglutination (28) or by indirect immunofluorescence assay (IIFA) (14) . The latex agglutination test for the diagnosis of cryptococcosis, which detects soluble C. neoformans capsular polysaccharide (CNPS) in the sera and cerebrospinal fluids of infected patients, is also routinely performed with polyclonal anti-CNPS antibodies (8). Finally, anti-CNPS antibodies contribute, with the techniques of carbohydrate chemistry, to the characterization of C. neoformans capsular components. The precise structure of the capsular mannan polysaccharides, including the epitope involved in serotype recognition, has not been totally elucidated, but subtle changes in sugar composition seem to be associated with serotype differences (25) . Monoclonal anti-CNPS antibodies might improve the results obtained with immune sera in the three areas cited above. In this paper, we report the production and characterization of, as well as the first results obtained with, a monoclonal mouse anti-CNPS antibody.
MATERIALS AND METHODS
CNPS purification. CNPS was purified by the method of Kozel and Cazin (17) (19) , we conducted preliminary studies designed to define the immunization procedures resulting in the highest level of antibody production. The following parameters were studied: route of administration, presence of adjuvant, number of immunizations, CNPS concentration, and strain and age of mice. Anti-CNPS antibody titers were determined by an IIFA 9 days after immunization. After the preliminary studies, BALB/c and C3HIHeJ mice aged 3 months or more were injected intravenously with 1 ,ug of CNPS. Antibodyproducing cells, estimated by rosette-forming cells (4) with CNPS-coated sheep erythrocytes (18) , were counted in the spleens 3 to 7 days after primary immunization. Fusions were performed the day before the peak of anti-CNPSsecreting cell proliferation.
Production of hybridomas. The procedure used for the production of hybridomas was derived from the protocol described by Kohler and Milstein (15) . The spleens were aseptically removed from the immunized mice, minced through a sterile screen, washed in minimal essential medium (MEM; GIBCO Laboratories, Grand Island, N.Y.), and centrifuged at 400 x g for 5 min. The cells were resuspended in 10 ml of MEM, and counts of viable cells were made after Trypan blue dye exclusion. Spleen cells and murine myeloma cells (P3X63-Ag8 653) were mixed (10:1) and centrifuged for 10 min at 400 x g. The pellet was resuspended in a drop of MEM, and 0.8 ml of a 45% solution of sterile polyethylene glycol 1000 was added for 1 min with gentle shaking. After a 3-min incubation at room temperature, the reaction was stopped by dilution with 10 ml of MEM for 5 min. The cells were centrifuged for 5 min at 400 x g, suspended in MEM supplemented with 10% horse serum, 1% glutamine, 1% pyruvate (GIBCO), gentamicin (100 ,uag/ml), penicillin (100 U/ml), 1% hypoxanthine (Sigma Chemical Co., St. Louis, Mo.), and 1% azaserine (Sigma) , and plated at 106 cells in 0.75 ml of medium per well of a 24-well culture plate (Becton Dickinson Labware, Oxnard, Calif.).
Hybridomas were detected microscopically after 10 days of culture at 37°C in a 10% CO2 incubator. The supernatants were screened by an enzyme-linked immunosorbent assay (ELISA) for anti-CNPS antibody production. Selected hybridomas were cloned by limiting dilution (0.5 cell per well in microplates; Becton Dickinson), and all positive hybridomas and clones were expanded in petri culture dishes (Becton Dickinson) and frozen at -80°C. Some clones were injected into pristane-primed mice for production of ascites.
Detection of anti-CNPS antibodies. Anti-CNPS antibodies were detected in supernatants from hybridomas by ELISA. The procedures used were modifications of the original procedure described by Engvall and Perlman (9) . Polystyrene 96-well microtiter plates (A/S NUNC, Roskilde, Denmark) were used for the solid phase. A 100-,ul sample of CNPS antigen per well, diluted to 10 ,ug/ml in 10 mM PBS (pH 7.4), was incubated at 37°C for 1 h. The plates were washed twice with PBS and once with PBS containing 3% bovine serum albumin (Sigma; PBS-BSA). Unbound sites were reacted for 1 h with 100 ,ul of PBS-BSA. The plates were then washed twice with PBS containing 0.1% Tween 20 (Sigma; PBS-Tween) and once with PBS-BSA-Tween. Duplicate samples (50 ,ul) of undiluted supernatants were incubated for 1 h at 37°C. After the plates were washed as described above, 50 ,ul of a horseradish peroxidase-labeled goat immunoglobulin G (IgG) anti-mouse immunoglobulin (Nordic Immunological Laboratories, Tilburg, The Netherlands) diluted 1:5,000 in PBS-BSA-Tween was added. After the plates were washed, o-phenylenediamine diluted at 4 mg/ml in citrate buffer (pH 5.6) was used as a substrate; 100 ,u1 of the solution was incubated at room temperature for 10 min, and the reaction was stopped by the addition of 20 ,ul Briefly, cells were suspended at 107/ml after four washings in PBS, and 10 RI of the suspension was incubated in each well of 10-well immunofluorescence slides. The slides were then air dried, heat fixed for 30 min, and stored at -30°C. Sera or monoclonal antibodies (25 ,ul) diluted in PBS were incubated at room temperature for 30 min in a moist chamber. The slides were washed three times in PBS. Anti-CNPS antibodies were detected by using fluorescein-labeled goat immunoglobulins (Nordic) that were specific for mouse polyvalent immunoglobulins. Fluoresceinated antibodies were diluted 1:100 in PBS and incubated for 30 min at room temperature. The slides were then washed, dried, covered with buffered glycerol, and examined under a Zeiss epifluorescence microscope. Control wells incubated with normal mouse serum were consistently negative. Serial 10-fold dilutions were tested, and the minimum antibody concentration at which fluorescence could be clearly observed was recorded. The patterns of fluorescence with the four serotypes were studied with monoclonal antibodies diluted in PBS at 100 ,ug/ml. All The fourth method, ELISA, was performed as follows. Serial 10-fold dilutions of the monoclonal antibodies were tested as described above on plates coated with 10 ,ug of CNPS of the A, B, C, or D serotype per ml, and the minimum antibody concentration giving a positive reaction was recorded.
The fifth method, competitive-binding assays, was performed as follows for soluble antigens. Antibody specificity was studied by competitive-binding assays in which increasing concentrations of various antigens diluted in PBS-BSATween were incubated (vol/vol) for 1 h at 37°C with 20 ng of antibody per ml. The ELISA was then performed in duplicate as described above in wells coated with CNPS A. The percentage of inhibition of anti-CNPS A antibody activity was calculated by the following formula: % inhibition = (max -exp)/(max -min) x 100, where max is the anti-CNPS A activity of unabsorbed antibody, exp is the residual anti-CNPS A activity of absorbed antibody, and min is the nonspecific binding to plastic. All values were expressed as arbitrary units of absorbance. Competitive-binding studies were performed with CNPS A, B, C, and D, constituent monosaccharides (mannose, xylose, galactose, and glucuronic acid), glucuronoxylomannan (GXM) purified from the four serotypes (GXM A, GXM B, GXM C, and GXM D), galactoxylomannan (GalXM), and mannoprotein purified from J67, an acapsular mutant (purified GXM from the four serotypes, GalXM, and mannoprotein were gifts from R. Cherniak, Atlanta, Ga.). A mannan from Saccharomyces cerevisiae (Sigma) was also tested because it contains a(1-+3) diamannoside structures (5), as does the mannan backbone of C. neoformans GXM.
For yeast cells, competitive-binding assays were also performed with C. neoformans strains from the different serotypes and other yeasts that have been reported to cross-react with CNPS (1, 2, 5, 11, 22), i.e., Cryptococcus laurentii (IP 1276-81), Candida albicans (IP 884), Trichosporon beigelii (IP 1557), Histoplasma capsulatum (IP 1052), and Histoplasma duboisii (IP 1098). The cells were harvested from Sabouraud slants; they were heat killed at 80°C for 1 h and washed three times in PBS. They were suspended in PBS-BSA-Tween at 109 cells per ml (for Histoplasma cells, the concentration was adjusted according to the A650 given by a suspension of 109 cells per ml or C. neoformans serotype A). Serial 10-fold dilutions were incubated (vol/vol) with 20 ng of antibody per ml. After 1 h of incubation at 37°C and one centrifugation (20 min at 1,000 x g), 50 ,ul of supernatant was deposited in duplicate into wells coated with CNPS A, and anti-CNPS A residual activity was measured. The percentage of inhibition was calculated as described above for soluble antigens. 21 hybridomas, 7 were IgG-and 14 were IgMsecreting cells. Six hybridomas with the highest level of antibody production (A492 on CNPS-coated wells of over 1.0) were cloned. Two stable clones (E1 and G1) producing monoclonal antibodies at significant levels were obtained from the C3H/HeJ cell fusions.
Characteristics of monoclonal antibodies. E1 and G1 monoclonal antibodies were eluted from a protein A-Sepharose column at pH 3.5. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed entire IgG with different isoelectric patterns (data not shown). The isotypes were IgGl in both cases.
Antibody activity. Since results were similar for E1 and G1, only the experiments performed with E1 will be presented in detail. Antigen-binding studies involving whole C. neoformans cells of the different serotypes (agglutination and IIFA) or purified CNPS (precipitation and ELISA) were performed ( Table 1) . E1 could precipitate with CNPS A by immunodiffusion ( Fig. 1) and could agglutinate C. neoformans A cells. A 1-ng amount of antibody per ml could be detected by IIFA or ELISA. E1 was specific for C. neoformans A cells by IIFA when used at 0.1 ,ug/ml or less. Cross-reactivity with C. neoformans B and D cells could be detected by IIFA by using E1 at a concentration of 1 pug/ml of more, but fluorescent patterns were distinct for the four serotypes (Fig. 2) were consistent with the patterns described above and were also obtained on smears made from isolated colonies.
To better define the structure involved in antibody recognition on CNPS A, we performed competitive-binding assays in which residual anti-CNPS A activity was measured by ELISA after incubation of E1 with soluble antigens. As indicated in Fig. 3a , E1 reacted with GXM but not with GalXM. No inhibition was detected with mannoprotein, with the constituent monosaccharides of CNPS, or with an S. cerevisiae mannan containing a(1->3) dimannoside structures (data not shown).
Competitive-binding studies allowed the evaluation of the specificity of E1 for C. neoformans A, CNPS A, and GXM A. Studies performed with soluble antigens showed (Fig. 3b) that E1 was specific for CNPS A; 50% inhibition of anti-CNPS activity required less than 1 ,ug of CNPS A per ml, whereas 7% or less inhibition was achieved with CNPS from the other serotypes at 1 mg/ml. However, studies with purified GXM showed that GXM D was a better inhibitor of E1 anti-CNPS A activity than CNPS D was. Little or no inhibition was observed with GXM B (Fig. 3b) or with GXM C (data not shown). Tests performed with whole yeasts (Fig.  4) (11) . The paucity of reports can be due in part to the poor anti-CNPS antibody response elicited in mice (19) and humans (12) after specific immunization. For this reason, we conducted preliminary immunization studies (data not shown) testing the influence of strain and age of mice, total dose and number of injections of antigen, route of administration, and presence of adjuvant on the level of antibody response. We selected one intravenous injection of 1 p,g of CNPS in at least 3-month-old BALB/c and C3H/HeJ mice as the best protocol, giving an anti-CNPS antibody serum titer over 1:1,000 by IIFA 9 days after immunization. Closely related conditions for immunization have been used by others with dextran (26) . Fusions were performed during the phase of rapidly proliferating antibody-secreting cells in the spleen; antibody-producing cells were estimated as rosette-forming cells with CNPScoated sheep erythrocytes. Although we used carefully primed cells for fusion with mouse myeloma cells, the yield of positive hybridomas was low, i.e., 0.4% with C3H cells and 2% with BALB/c cells. Two clones, purified from the two hybridomas obtained with C3H cells, were expanded in ascites. The corresponding antibodies were purified on a protein A-Sepharose column and analyzed for isoelectric forms, isotypes, and antibody activities. The two antibodies had different isoelectric patterns but had the same IgGl isotype and similar in vitro activities. Therefore, only the results obtained with one of them (E1) are discussed in this paper.
CNPS purified from C. neoformans serotype A consists of 88% GXM, 11% GaIXM, and approximately 1% mannoprotein (6, 27) . The GXM backbone consists of a linear a(1-*3)-linked mannan substituted at 2-o positions by single residues of either xylose or glucuronic acid (5, 23) . The GXM structure has been analyzed by biochemical, immunological, and nuclear magnetic resonance studies (25) . The most likely GXM hapten configuration reported (5) is a tetrasaccharide consisting of xylose and glucuronic acid, both linked to a mannose a(1-*3) disaccharide. Subtle differences involving the relative proportion of xylose and glucuronic acid residues, the degree of mannan substitution, and the percentage of o-acetyl attachments (20) seem to be responsible for the distinctions among the four serotypes described with immune sera (28) . Monoclonal antibodies could give some insight into the GXM structure and the epitope configuration involved in serotype definition. E1 reacted with the GXM component of CNPS but not with GalXM and mannoprotein, since only GXM was able to inhibit anti-CNPS A activity. Anti-CNPS A activity could not be inhibited by the constituent monosaccharides or a mannan purified from S. cerevisiae. This suggests that E1 does not react with the mannose a(1-*3) disaccharide, since the same structure is also present on S. cerevisiae mannan (10) . Further studies are warranted to better assess the precise target of E1 activity.
To evaluate whether E1 was specific for CNPS purified from C. neoformans serotype A, studies were performed using whole cells from the four serotypes (agglutination and IIFA) as well as the corresponding purified CNPS (precipitation and ELISA). Competitive-binding studies were also performed as more sensitive techniques. Agglutination studies suggested that E1 is specific for C. neoformans serotype A, and immunodiffusion experiments indicated that El is specific for CNPS A. However, more sensitive techniques revealed a certain extent of cross-reactivity; binding to serotype B and D cells was detected by IIFA at an E1 concentration 1,000 times higher than that needed to label serotype A cells. Competitive-binding studies confirmed IIFA results, showing that high concentrations of CNPS B and CNPS D, but not of CNPS C, could inhibit less than 10% E1 anti-CNPS A activity. Comparison of the ability of GXM from the four serotypes to inhibit E1 anti-CNPS A activity showed that the highest level of inhibition was obtained with GXM A, whereas no inhibition was observed with GXM C. anti-CNPS A activity than CNPS D was. Inhibition studies performed with C. neoformans cells from the four serotypes confirmed the results obtained by IIFA studies; i.e., concentrations of serotypes B and D cells 10,000 times higher than that of serotype A were needed for a 50% inhibition of El anti-CNPS A activity. C. neoformans cells of serotypes A, D, and to a lesser extent B are known to exhibit a certain degree of cross-reactivity with polyclonal immune serum raised after immunization with A cells (13, 14, 28 (22) . C. neoformans serotyping requires properly absorbed anti-CNPS immune serum (14, 28) . Monoclonal anti-CNPS antibodies could be of value for two reasons. First, E1 was specific for serotype A without requiring absorption when used at 100 ,ug/ml or less for agglutination or at 0.1 ,ug/ml or less for IIFA. Second, distinct patterns of fluorescence were observed with cells from the four serotypes incubated with E1 at 10 to 100 ,ug/ml; all serotype A cells appeared brightly fluorescent, whereas serotype C cells were consistently negative. The overall fluorescent intensity on B and D smears was lower than that on A smears, and the amount of fluorescence was highly variable from one cell to another, from brightly fluorescent to negative cells. Such fluorescent diversity was not observed on serotype A smears, even when E1 was diluted, and did not result from contamination, since the same pattern was observed on smears made from isolated colonies. Serotype D cells could be readily distinguished from serotype B cells, since positive D cells had a homogeneous aspect, with a rim reinforcement identical to that observed with A cells, whereas B cells appeared speckled.
Immune anti-CNPS antibodies are routinely used for the serological diagnosis of cryptococcosis. When coating latex particles, they give a positive agglutination reaction in the presence of soluble CNPS in sera or cerebrospinal fluids from infected patients. Commercial kits are available and give a positive reaction for a CNPS concentration above 0.02 ,ug/ml (29) . Monoclonal anti-CNPS antibodies reacting with the four serotypes might be preferred to polyclonal immune sera because they would allow a better standardization of the test. Moreover, preliminary results suggest that approximately 1 ng of CNPS A per ml can be detected by a sensitive test (competitive-binding enzyme immunoassy) using E1.
In conclusion, monoclonal anti-CNPS antibodies should be developed because they may serve several purposes, i.e., a better knowledge of the structure of CNPS, a simple serotyping method, and possibly an improvement in cryptococcosis diagnostic procedures. Finally, mouse monoclonal antibodies could contribute to the treatment of experimental murine cryptococcosis, and this topic is addressed in the accompanying paper (7) .
